Mostrando 10 resultados de: 12
Publisher
Cancer Immunology, Immunotherapy(2)
Clinical Cancer Research(2)
Annals of Oncology(1)
BioPharm International(1)
Biotecnologia Aplicada(1)
Área temáticas
Enfermedades(10)
Farmacología y terapéutica(5)
Fisiología humana(2)
Bioquímica(1)
Física aplicada(1)
Área de conocimiento
Cáncer(9)
Inmunología(6)
Ingeniería de manufactura(1)
Medicamento(1)
Medicina interna(1)
Origen
scopus(12)
Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
ArticleAbstract: Aging is considered the single most significant risk factor for the majority of common malignances iPalabras claves:B cells, Epidermal growth factor, Pro-inflammatory cytokines, T cells, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Cordero L., García Verdecia B., González A., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Pereira K., Saavedra Hernández D., Salomón E.E., Sánchez M.G., Suárez G.M., Tania CrombetFuentes:scopusBiomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients
ArticleAbstract: Purpose: There are well-known alterations occurring within the immune system with aging. CollectivelPalabras claves:cancer vaccine, Immunosenescence, Immunosenescence markers, Non-small cell lung cancerAutores:Fuentes K.P., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Popa X., Saavedra Hernández D., Tania CrombetFuentes:scopusBiomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly
ArticleAbstract: The changes that occur in the immune system with aging are commonly termed immunosenescence. ImmunosPalabras claves:Biomodulina T, Immunosenescence, naïve T cells, Stem cell-like memory T cells, T cellsAutores:Aznar E., Fuertes S.A., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Saavedra Hernández D., Speiser D.E., Suárez G.M., Tania CrombetFuentes:scopusAnti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
ArticleAbstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advancPalabras claves:antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarkerAutores:Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania CrombetFuentes:scopusA Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusCIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer
ReviewAbstract: Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and its role in tPalabras claves:cancer vaccine, clinical trials, Epidermal growth factor, Epidermal growth factor receptor, lung cancer, Non-small-cell lung cancerAutores:García Verdecia B., Lage Davila A., Neninger Vinageras E., Rodríguez P.C., Tania CrombetFuentes:scopusCIMAvax-EGF: A novel therapeutic vaccine for advanced lung cancer
ArticleAbstract: The results allowing the Cuban Regulatory Agency (CECMED) to grant the Sanitary Registration to thePalabras claves:cancer vaccine, CIMAvax-EGF, Fast-Track registration, NSCLC, Phase II-III clinical trialAutores:Arteaga N., Cuevas A., García Verdecia B., González G., Lage Davila A., Neninger Vinageras E., Rodríguez G., Tania Crombet, Viña L.Fuentes:scopusEpidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
ArticleAbstract: Background: The role that growth factors and their receptors play in human cancer growth and progresPalabras claves:cancer vaccine, Epidermal growth factor, Non-small-cell lung cancerAutores:Alfonso L., Catala M., García Verdecia B., González G., Lage R., Mulet A., Neninger Vinageras E., Osorio M., Pérez R., Tania Crombet, Torres F.Fuentes:scopusEffective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine
ArticleAbstract: Purpose: Epidermal growth factor (EGF) might be a suitable immunotherapeutic target in non-small-celPalabras claves:Autores:Carmen Elena Viada, De La Torre A.V., García Verdecia B., González G., Lage Davila A., Leonard I., Martínez R., Mazorra Z., Neninger Vinageras E., Tania CrombetFuentes:scopusManufacturing process development for an epidermal growth factor-based cancer vaccine
ArticleAbstract: The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapyPalabras claves:Autores:Albisa A., Calvo L., Chico E., Cuevas A., Garcia A.T., García Verdecia B., González G., Portillo A., Rodríguez G., Tania Crombet, Viña L.Fuentes:scopus